Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterised by persistent inattention, hyperactivity, and impulsivity. Although traditional treatments include medications and behavioural interventions, neurofeedback therapy has emerged as an effective, evidence-based alternative or complementary approach.

ADHD involves complex neurological dysregulation, particularly affecting the brain’s frontal and prefrontal cortex regions responsible for attention, impulse control, and executive function. Research using quantitative electroencephalography (qEEG) has identified common brainwave patterns in individuals with ADHD, notably an elevated theta/beta ratio, reflecting reduced cortical activation and vigilance (Arns et al., 2013).

Neurofeedback, a form of biofeedback, trains individuals to self-regulate their own brain activity. By using real-time feedback of their EEG signals, clients learn to enhance desirable brainwave patterns and reduce dysfunctional ones. For ADHD, neurofeedback often targets normalising the theta/beta ratio, thus promoting better attention, reduced impulsivity, and improved executive functioning.

In one meta-analysis, significant clinical improvements were observed in attention and hyperactivity following neurofeedback training, with effects persisting even months after treatment ended (Van Doren et al., 2019).

At Headquarters, neurofeedback protocols are individualised based on qEEG assessments. These brain mappings precisely identify dysregulated areas, allowing for personalised and targeted therapy. Research supports that individualised qEEG-guided neurofeedback protocols lead to superior outcomes compared to standardised approaches (Krepel et al., 2020).

Multiple scientific studies support neurofeedback's efficacy in reducing ADHD symptoms. For instance, a randomised controlled trial found significant improvements in impulsivity and attention in children who underwent neurofeedback compared to control groups (Steiner et al., 2014). Another recent systematic review indicated long-term improvements in academic performance and behavioural control following neurofeedback training (Enriquez-Geppert et al., 2019).

Our clinic employs advanced neuroscientific methods grounded in the latest research, offering a drug-free, effective way to manage ADHD symptoms. Clients typically report noticeable improvements in concentration, emotional control, and daily functioning after completing their neurofeedback training.

Neurofeedback therapy presents a scientifically validated and effective approach to managing ADHD. By directly addressing the neurological roots of attentional and impulse-control issues, neurofeedback provides a pathway towards sustained improvements in everyday life.

References

Arns, M., Conners, C. K., & Kraemer, H. C. (2013). A decade of EEG Theta/Beta Ratio Research in ADHD: a meta-analysis. Journal of attention disorders, 17(5), 374–383. https://doi.org/10.1177/1087054712460087 

Van Doren, J., Arns, M., Heinrich, H., Vollebregt, M. A., Strehl, U., & K Loo, S. (2019). Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis. European child & adolescent psychiatry, 28(3), 293–305. https://doi.org/10.1007/s00787-018-1121-4

Krepel, N., Egtberts, T., Sack, A. T., Heinrich, H., Ryan, M., & Arns, M. (2020). A multicenter effectiveness trial of QEEG-informed neurofeedback in ADHD: Replication and treatment prediction. NeuroImage. Clinical, 28, 102399. https://doi.org/10.1016/j.nicl.2020.102399

Steiner, N. J., Frenette, E. C., Rene, K. M., Brennan, R. T., & Perrin, E. C. (2014). Neurofeedback and cognitive attention training for children with attention-deficit hyperactivity disorder in schools. Journal of developmental and behavioral pediatrics : JDBP, 35(1), 18–27. https://doi.org/10.1097/DBP.0000000000000009 

Enriquez-Geppert, S., Smit, D., Pimenta, M. G., & Arns, M. (2019). Neurofeedback as a Treatment Intervention in ADHD: Current Evidence and Practice. Current psychiatry reports, 21(6), 46. https://doi.org/10.1007/s11920-019-1021-4